Business
Zai Lab Announces Dosing of First Participant in Global Phase 1/1b study of ZL-1503, an IL-13/IL-31R Bispecific Antibody for the Treatment of Atopic Dermatitis
SHANGHAI & CAMBRIDGE, Mass., December 08, 2025--Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced the dosing of the first participant in a global Phase 1/1b clinical trial evaluating the safety, tolerability, pharmacokinetics, and efficacy of ZL-1503, a potential first-in-class IL-13/IL-31R bispecific antibody for the treatment of atopic dermatitis (AD). ZL-1503, which was identified and advanced internally by Zai Lab’s discovery team, targets both IL-13 and IL-31 pathways with an exten
About this update from Zai Lab Ltd.
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":480,"height":224,"url":"https://media.zenfs.com/en/business-wire.com/507af40927df6bfc4efbb7743c5d4d74"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/NiN2LJpnjF5YsVRmN6L5pA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTQ0ODtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/507af40927df6bfc4efbb7743c5d4d74","width":480,"height":224}},"lazy":false},{"type":"text","content":"- ZL-1503, a promising treatment for moderate-to-severe atopic dermatitis and other Type 2 helper T-cell (Th2)-driven diseases, strengthens Zai Lab’s growing global pipeline","length":173,"tagName":"p"},{"type":"text","content":"- ZL-1503 originated from Zai Lab’s in-house discovery and development engine","length":77,"tagName":"p"},{"type":"text","content":"SHANGHAI & CAMBRIDGE, Mass., December 08, 2025--(BUSINESS WIRE)--Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced the dosing of the first participant in a global Phase 1/1b clinical trial evaluating the safety, tolerability, pharmacokinetics, and efficacy of ZL-1503, a potential first-in-class IL-13/IL-31R bispecific antibody for the treatment of atopic dermatitis (AD). ZL-1503, which was identified and advanced internally by Zai Lab’s discovery team, targets both IL-13 and IL-31 pathways with an extended serum half-life. The dual targeting potentially provides faster onset of action and superior efficacy.","length":627,"tagName":"p"},{"type":"text","content":"In preclinical studies, ZL-1503 demonstrated the ability to simultaneously suppress inflammatory and pruritogenic (itch-causing) pathways implicated in AD. These findings, recently presented at the European Academy of Allergy and Clinical Immunology (EAACI) 2025 Congress, highlight ZL-1503’s potential as a novel therapeutic option for patients with moderate-to-severe AD.","length":373,"tagName":"p"},{"type":"text","content":""The progress of ZL-1503 is another strong example of our global development capabilities, underscoring the speed, scientific rigor and operational excellence of our team," said Rafael G. Amado, M.D., President, Head of Global Research and Development, Zai Lab. "Importantly, ZL-1503 has the potential to provide patients with a novel and much-needed treatment option for mana...